Summary A comparison has been made of the cachectic effects produced by the transplantable murine adenocarcinoma of the mouse colon (MAC16) with tumour necrosis factor-a (cachectin). Tumour necrosis factor-a (TNF-a) produced a dose-related weight reduction that was accompanied by a decrease in both food and water intake. The degree of weight loss was directly proportional to the decreased food and water intake. In contrast weight loss produced by the MAC16 tumour occurred without a reduction in fluid or nutrient intake. Both the MAC16 tumour and TNF-a produced hypoglycaemia and a reduction in the circulatory level of free fatty acids (FFA), but had opposite effects on the level of plasma triglycerides with the MAC16 tumour-induced cachexia causing a decrease and TNF-a producing an increase. The MAC16 tumour elaborated a lipolytic factor which caused an immediate release of FFA from adipose tissue. In contrast TNF-a had no effect on mobilization of adipose triglycerides over a short time period. Both TNF-a and extracts from the MAC16 tumour caused an enhanced release of amino acids from mouse diaphragm, which was suppressible with indomethacin and heat labile. No TNF was detected in the MAC16 tumour or in the serum of tumour-bearing animals. Both tumour and non-tumour-bearing animals responded with a similar elevation of their serum TNF levels 90min after a single injection of endotoxin. It is concluded that weight loss produced by TNF-a arises from an anorexic effect and that this differs from the complex metabolic changes associated with cancer cachexia.
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We have been investigating a chemically induced, transplantable adenocarcinoma of the colon (MAC 16), passaged in inbred NMRI mice as an experimental model of cachexia (Bibby et al., 1987) . This tumour produces weight loss at small tumour burdens (<1% of the host wcight) and without a reduction in the intake of either food or water. The weight loss, which is directly proportional to the tumour weight, is associated with a decrease in both carcass fat and muscle dry weight (Beck & Tisdale, 1987) . The cachectic effect of the tumour has been attributed to the production of both lipolytic and proteolytic factors, which are present in the circulation of tumour-bearing animals.
Endotoxin-induced cells of the reticuloendothelial system have been shown to elaborate a mediator called cachectin (tumour necrosis factor, TNF), which induces a state of cachexia in recipient animals . When chronically secreted by host macrophages cachectin has been suggested to contribute to a catabolic state, which ultimately leads to cachexia (Beutler & Cerami, 1986) . Torti et al. (1985) have shown that cachectin acts to suppress the biosynthesis of several adipocyte-specific mRNA molecules and prevents morphological differentiation of pre-adipocytes. Lipoprotein lipase is one of the many enzymes whose transcription is suppressed by the action of this hormone (Price et al., 1986b (Beutler & Cerami, 1986 (Bibby et al., 1987 Gifford (1984, 1986 (Beck & Tisdale, 1987) , and incubations were normally conducted for a 2 h period at 37 C. The concentration of FFA in the cell-free supernatants was determined immediately using a Wako NEFA C kit.
Determination of proteolytic activity Male BALB/c mice were killed by cervical dislocation and diaphragms were carefully dissected out, blotted, cut in half, weighed and each half placed in a stoppered vial containing 0.75 ml Krebs-Ringer bicarbonate buffer and gassed for 20 sec with 5% CO2 in air. Preincubations were carried out for 30min at 37°C, and the diaphragms were then blotted and transferred to clean vials containing either tumour extract or TNF and the Krebs-Ringer buffer, in a total volume of 0.75 ml. The vials were gassed and incubated for a further 2h at 37°C. Incubations were terminated by mixing 0.5 ml assay mixture with 0.125 ml of cold 50% TCA, mixing and centrifuging for 10min at 3000rpm. The supernatants were neutralised with I N NaOH and 0.2 ml of the neutralised sample was mixed with 1 ml of ninhydrin reagent, held in a boiling water bath for 20 min, and after dilution to 5 ml with n-propanol:water (1: 1), the concentration of amino acids was determined spectrophotometrically at 570 nm. The spontaneous release of amino acids from the diaphragms in the absence of any additions was subtracted from the final readings.
Results
The characteristics of weight loss produced by the MAC 16 adenocarcinoma passaged in NMRI mice has previously been reported (Bibby et al., 1987, Beck and .
Briefly weight loss starts to occur when the tumour mass exceeds 0.1 g and reaches 10 g in a 30 g male mouse when the tumour mass is 0.7 g, representing just 2% of the weight of the animal. Both muscle and adipose mass decrease in direct proportion to the weight of the tumour (Beck & Tisdale, 1987) . The average food intake in MAC16 tumour-bearing animals (15.1 + 0.6 kcal day -1) is not significantly different from that in non-tumour-bearing animals (I14.9 + 0.9 kcal day -1). Also the water intake in tumourbearing animals (4.6 + 0.27 ml day-1) does not differ from that of controls (4.8+0.16mlday-1). We have used female NMRI mice to study weight loss induced by TNF-a since they display a less aggressive behaviour than males, which may result in selective individuals being deprived food and water. Human recombinant TNF-a administered i.v. causes a dose-related weight loss after two separate injections over a 24h period (Figure 1) , which is significantly greater than saline injected controls at all concentrations of TNF-at employed. Qualitatively similar results were obtained with murine recombinant TNF-cx, obtained from Dr W. Fiers, Biogent, Belgium (Marmenout et al., 1985) . No mortality was observed with any of the concentrations of TNF-a. This weight loss differs from that observed in MAC16 tumour-bearing animals in that it is associated with a dose-dependent decrease in both food (Figure 2) and water (Figure 3 ) consumption. The decrease in food and water intake is directly proportional to the decrease in body weight (Figure 4) . Weight gain (g) Figure 4 Variation of weight loss during a 24h period after administration of TNF-a with the difference in food (kcal/mouse) and water (ml) consumption between a saline infused group and the TNF-a treated groups. The results were fitted to a linear model by means of a least squares analysis (r = -0.99).
Animals bearing the MAC16 tumour display a reduced blood glucose level. TNF-a treated mice also show a highly significant dose-related hypoglycaemia, which is much more pronounced than observed in weight-losing tumour-bearing animals (Table I) . Plasma triglyceride levels are also reduced in tumour-bearing animals, whereas TNF-oa causes an increase in circulatory triglycerides, presumably due to an inhibition of adipocyte lipoprotein lipase activity (Table I) .
Plasma levels of FFA are reduced after TNF-a administration, as might be expected from an inhibition of lipoprotein lipase and also in tumour-bearing animals, possibly due to increased tumour utilization.
The loss of body fat in MAC16 tumour-bearing animals has been correlated with the presence of a lipolytic substance produced by the tumour (Beck and Tisdale, 1987) . This material is quantitated by the extent of release of FFA from mouse epididymal adipocytes. The results in Table II show that while extracts of the MAC16 tumour cause an enhanced release of FFA, TNF-a has no effect on the release of FFA under the conditions of the assay up to a concentration of 4 x 105 units ml-'. The MAC16 tumour also has high levels of proteolytic activity, which may be responsible for the muscle wasting (Beck & Tisdale, 1987) (Figure 5 ). Using the mouse diaphragm as a model of skeletal muscle, TNF-oa at high concentrations also causes an enhanced release of amino acids ( Figure 5 ). This effect is not due to contamination by endotoxin, since when the TNF-a is heated to 70°C for 15min, which should destroy the TNF, but does not affect endotoxin, the proteolytic activity is completely destroyed. The proteolytic effect of TNF-a is almost completely suppressed by indomethacin and human a-I antitrypsin. The proteolytic activity of the MAC16 tumour extract is also partially suppressed by indomethacin and there is a synergistic inhibition by a combination of indomethacin and antitrypsin ( Figure 5 ). Proteolysis by trypsin is also inhibited by indomethacin. An enhanced amino acid release is also observed when diaphragms are incubated in the presence of PGE2 or PGEJ, but not in the presence of PGFia or PGF2,, (Table III) .
No TNF was detected either in the MAC 16 tumour or in the serum of tumour-bearing mice using the L929 cytotoxicity assay. TNF was detected in the serum of nontumour-bearing animals and in the serum of animals bearing the MAC 16 and the non-cachexia inducing colon adenocarcinoma, MAC13, 90min after a single i.v. injection of 25 jug endotoxin (Figure 6 ). However, there was no difference in the extent of response between non-tumour-bearing animals and animals bearing either type of tumour or in the levels of TNF in the two tumour types.
Discussion
The MAC16 tumour can be considered as an appropriate model for human cancer where weight loss occurs due to the biochemical effect of the tumour in patients with adequate release; bp < 0.05 from nutrient intake and without intestinal malfunction. In contrast TNF induces a state of anorexia and the ensuing weight loss is directly proportional to the decrease in food and water intake. A similar effect has been observed in mice injected with dialyzed conditioned medium obtained from lipopolysaccharide-induced peritoneal macrophages . Although all the experiments have been performed with human TNF-oa similar results were obtained with murine TNF-cx. Marmenout et al. (1985) have shown that in spite of the apparent species specificity of TNF, human TNF is about 80% homologous to mouse TNF, and its hydrophilicity plot is also very similar.
The weight loss produced by both TNF-ax and the MAC16 tumour is associated with hypoglycaemia, although TNF produces a more marked and possibly life-threatening decline in blood glucose levels. While administration of lipopolysaccharide has been shown to induce hypoglycaemia, Satomi et al. (1985) reported no hypoglycaemia in mice administered highly purified TNF. However, Kettlehut et al. (1987) have recently demonstrated large biphasic changes in blood glucose levels after TNF injection, with an initial hyperglycaemia followed by a sharp decrease in blood glucose. It has been suggested (Kettlehut et al., 1987) that TNF may stimulate glucose uptake and oxidation contributing to the severe hypoglycaemia. In contrast the hypoglycaemia observed in animals bearing the MAC16 tumour probably arises from an increased consumption of glucose by the tumour (Tisdale & Brennan, 1986) .
The MAC16 tumour and TNF-cx differ as regards their effect on lipid metabolism in weight-losing animals. Thus, whereas animals bearing the MAC16 tumour have a reduced circulatory level of both FFA and triglycerides, TNF-oa causes an increase in plasma triglyceride levels probably due to an inhibition of lipoprotein lipase activity. While lipoprotein lipase activity has been shown to be decreased in mice with the development of Sarcoma 180 (Masuno & Okuda, 1986) we have no evidence for an effect on lipoprotein lipase activity in animals bearing the MAC 16 tumour, despite a massive loss of adipose tissue. This catabolism of adipose tissue has been attributed to the production by the tumour of a lipolytic factor (Beck & Tisdale, 1987) . However, we have observed no increased breakdown of stored triglycerides in adipose tissue in the presence of TNF-ax. While Kawakami et al. (1987) have reported that TNF-x increased the lipolysis of stored fat in 3T3-L1 adipocytes, even in the presence of 50ng ml-1 of insulin, Price et al. (1986b) have shown that while crude preparations of TNF were able to suppress the activity of key lipogenic enzymes and stimulate lipolysis, recombinant TNF-a had no effect on either the ability of the adipocytes to synthesize and store or to mobilize triacylglycerols. The lipolytic activity of stimulated macrophages was attributed to interleukin 1, which both suppressed lipoprotein lipase activity and stimulated lipolysis (Price et al., 1986a) . Another possible reason for the absence of lipolysis we observed with our TNF-oa preparation was the relatively short incubation time that we employed (2h). Kawakami et al. (1987) in 3T3-L1 cells until 12 h after the addition of TNF-a, after which there was a linear increase in production up to 24 h. Kettlehut et al. (1987) have shown that the toxic and metabolic effects of TNF probably arise from an increased prostaglandin E2 production since the cyclooxygenase inhibitors indomethacin or ibuprofen administered before TNF reduced the lethality and changes in blood glucose. We have shown (Beck & Tisdale, 1988) that the lipolytic substance elaborated by the MAC16 tumour is not a prostaglandin since indomethacin had no effect on FFA release at concentrations up to 1 mM. The MAC 16 tumour also elaborates a serine-protease when measured by an accelerate rate of release of amino acids from mouse diaphragm as a model of skeletal muscle (Beck & Tisdale, 1987) . Using a similar assay we have detected a proteolytic activity associated with high level of TNF-ax. This activity was not due to the small amount of endotoxin contamination since it was destroyed by heating, and not due to the presence of endogenous proteases in the TNF-a preparation (Boehringer Ingelheim, pers. comm.) . Proteolysis induced by both TNF-a and the MAC16 tumour extract is suppressible by indomethacin suggesting the possibility of a prostaglandin intermediate. We have shown that prostaglandins of the E series, but not of the F, are also effective in inducing amino acid release from mouse diaphgram. PGE2 is believed to be an important stimulus for the production of intracellular proteases (Rodemann & Goldberg, 1982) . Moreover, TNF-a has been reported to stimulate collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts (Dayer et al., 1985) . This suggests that the enhanced release of amino acids from mouse diaphragm in the presence of TNF is due to an elevation of PGE2 levels.
We have been unable to detect TNF either in the MAC16 tumour, or in the serum of tumour-bearing animals. Animals bearing either the MAC1 6 or the non-cachexing-inducing MAC 13 colon adenocarcinomas do not respond to endotoxin with an increased TNF production compared with non-tumour bearing controls. This negates against a synergistic influence of the presence of a tumour on TNF production in response to endotoxin.
The results suggest that TNF has no role in the induction of cachexia seen in animals bearing the MAC16 tumour. Although we have compared the chronic secretion of factors produced by the MAC16 tumour with the acute effects of TNF we have shown (Mahony and Tisdale, unpublished results) that chronic exposure to TNF does not differ appreciably from the acute effects. Furthermore the weight loss produced by TNF appears to arise from an anorexic effect of this agent and this differs from the changes associated with cancer cachexia.
